Retrophin (RTRX) Misses Q1 EPS by 6c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Retrophin (RTRX) Misses Q1 EPS by 6c, Revenues Miss

Retrophin Reports First Quarter 2019 Financial Results

May 7, 2019 4:02 PM EDT

Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019

Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN

Continued quarter over quarter growth in net product sales

SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its first quarter 2019 financial results and provided a corporate update.

Top-line data from the pivotal Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration... More